These success, along with a earlier report displaying that a little-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like conduct in mice,two support the concept of targeting ACKR3 as a singular technique to modulate the opioid program, which could open new therapeutic avenues for opioid-connec